1. B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY. (5th April 2022) Authors: Rodriguez-Otero, P; Dholaria, B; Askari, E; Reece, D; van de Donk, N; Chari, A; Goldschmidt, H; Krishnan, A; Martin, T; Mateos, M; Morillo, D; Rodriguez, C; Rosinol, L; San-Miguel, J; Balari, A; Wäsch, R; Weisel, K; Verona, R; Lin, S; Prior, T Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. B05: RESULTS FROM A META-ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMPARED TO PHYSICIAN'S CHOICE OF TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA. (5th April 2022) Authors: Gay, F; Berdeja, JG; De Stefano, V; Hari, P; Hooper, B; Haltner, A; Kumar, S; Martin, T; Mateos, M-V; Moreau, P; Rosta, E; Samjoo, IA; Usmani, SZ; Weisel, K; Jackson, CC; Olyslager, Y; Schecter, JM; Vogel, M; Garrett, A; Lee, S Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OP24 Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn's Disease: Week 48 analyses from the phase 2 GALAXI 1 study. (21st January 2022) Authors: Danese, S; Panaccione, R; Rubin, D T; Sands, B E; Reinisch, W; D'Haens, G; Panés, J; Gonzalez, S; Weisel, K; Sahoo, A; Frustaci, M E; Yang, Z; Sandborn, W J; Afzali, A; Hisamatsu, T; Andrews, J M; Feagan, B Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i026 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OP28 The effect of guselkumab induction therapy on early clinical outcome measures in patients with Moderately to Severely Active Crohn's Disease: Results from the phase 2 GALAXI 1 study. (27th May 2021) Authors: Danese, S; Sandborn, W J; Feagan, B G; Weisel, K; Gonzalez, S; Frustaci, M E; Yang, Z; Johanns, J; Germinaro, M; Afzali, A; Andrews, J M; D'Haens, G; Hisamatsu, T; Panaccione, R; Reinisch, W; Rubin, D T; Sands, B E; Panes, J Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S027 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL. (5th April 2022) Authors: Sonneveld, P; Chanan-Khan, A; Weisel, K; Nooka, AK; Masszi, T; Beksac, M; Spicka, I; Hungria, V; Munder, M; Mateos, MV; Mark, TM; Levin, MD; Ahmadi, T; Qin, X; Garvin Mayo, W; Gai, X; Carey, J; Carson, R; Spencer, A Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. (5th April 2022) Authors: van de Donk, N. W. C. J; Popat, R; Hulin, C; Jagannath, S; Oriol, A; Richardson, P. G; Facon, T; Weisel, K; Larsen, J. T; Minnema, M; Abdallah, A; Badros, A. Z; Knop, S; Stadtmauer, E. A; Chen, M; Nguyen, T. V; Amin, A; Peluso, T; Lonial, S Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY. (5th April 2022) Authors: Einsele, H; Cohen, AD; Delforge, M; Hillengass, J; Goldschmidt, H; Weisel, K; Raab, M-S; Scheid, C; Schecter, JM; De Braganca, KC; Varsos, H; Yeh, T-M; Wang, L; Vogel, M; Corsale, C; Akram, M; Pacaud, L; Nesheiwat, T; Agha, M; Cohen, YC Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?. (5th April 2022) Authors: Popat, R; Badros, A; Kumar, S; Rodriguez-Otero, P; Cohen, A; Manier, S; Voorhees, P; Gay, F; Rifkin, R; Martin, T; Chari, A; Weisel, K; Farooq, A; Jeng, B; Chng, W; Lee, H; Berdeja, J; Jadhav, V; Tosolini, A; Eliason, L Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA. (5th April 2022) Authors: Usmani, S; Alonso, A; Quach, H; Koh, Y; Guenther, A; Min, CK; Leleu, X; Abdallah, AO; Oriol, A; Bessemer, B; Garg, M; Sandhu, I; Weisel, K; Ocio San Miguel, E; Cavo, M; Zhou, X; Kaisermann, M; Mis, L; Williams, D; Yeakey, A Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗